Monopar Insider Report: RSU Vesting Boosts CEO Stake to 82,198 Shares
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) director and CEO Dr. Robinson Chandler reported insider transactions on Form 4 showing restricted stock unit vesting and resulting share movements on 09/30/2025. He received 8,726 shares upon vesting and settlement of RSUs and had 2,646 shares withheld to satisfy withholding taxes, leaving 82,198 shares reported as directly owned after the transactions. The filing also discloses 272,026 shares held by Tactic Pharma LLC, over which Dr. Robinson may be deemed to share voting and dispositive power; he expressly disclaims beneficial ownership of those shares except to the extent of his pecuniary interest. Transactions are tied to multiple RSU grants made in 2022, 2023 and 2025 with scheduled vesting through December 31, 2028.
Positive
- 8,726 shares acquired on vesting and settlement of restricted stock units on 09/30/2025
- 2,646 shares withheld to satisfy withholding tax, indicating standard tax-withholding on equity compensation
- Disclosure of RSU grant schedules from 2022, 2023, and 2025 with clear vesting timelines through 12/31/2028
Negative
- Reporting person may be deemed to share voting and dispositive power over 272,026 shares held by Tactic Pharma LLC, though he disclaims beneficial ownership except for pecuniary interest
- RSU settlements and ongoing vesting schedules imply continued equity issuance/dilution through 12/31/2028
Insights
TL;DR: Insider vesting and significant indirect holdings change voting landscape.
The Form 4 documents vested restricted stock units that increased Dr. Robinson's direct share count to 82,198 and discloses 272,026 shares held by Tactic Pharma LLC over which he may share control. This dual disclosure matters for shareholder voting and control calculations because it separates direct ownership from potential shared control via an entity. The filing also includes an explicit disclaimer limiting his claimed beneficial ownership of the LLC's shares to his pecuniary interest.
TL;DR: Multiple RSU grants are vesting on schedule, producing immediate share issuance and tax-withholding.
The report lists the settlement of RSUs (including grants from 2022, 2023, and 2025) resulting in 8,726 vested shares delivered and 2,646 shares withheld for taxes on 09/30/2025. The filing documents the vesting schedules tied to those grants, with remaining RSUs scheduled to vest through December 31, 2028, showing ongoing equity dilution from compensation tied to these grants.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 8,726 | $0.00 | -- |
| Exercise | Common Stock | 8,726 | $0.00 | -- |
| Tax Withholding | Common Stock | 2,646 | $81.67 | $216K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents shares acquired on vesting and settlement of restricted stock units. Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 272,026 shares. Dr. Robinson disclaims beneficial ownership of the 272,026 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
